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Background: The manufacturers of Perfalgan®, a formulation of intravenous paracetamol, recommend that each ampoule be 
used once only. This is most likely due to concerns regarding degradation of paracetamol or other ingredients in the solution, 
and sterility issues. However, in South Africa, where the expense of this drug limits use, some centres use one ampoule for 
multiple paediatric cases over the course of 12–24 hours. No obvious clinical adverse effects have been reported.
Aim: The aim of this study was to examine this practice by assessing drug bioavailability as well as the in vitro stability of the 
paracetamol and excipients in Perfalgan® on exposure to air and specific stressors over time.
Methodology: High-performance liquid chromatography (HPCL-UV) was used to determine the concentration of paracetamol 
and the presence of degradation products in samples taken at set time intervals following exposure of Perfalgan® to air and 
stressors. Since changes in other components, or excipients, may impact efficacy, these were measured using nuclear magnetic 
resonance (1H NMR). The octanol:water partition coefficient was used as an indicator of bioavailability. Ultraviolet spectroscopy 
was used to calculate the penetration of paracetamol in Perfalgan® into the lipid layer.
Results: The paracetamol in Perfalgan® did not degrade on exposure to air over 24 hours. Neither did it degrade on exposure 
to acid, alkali, oxidative or heat stress. 1H NMR revealed no change in the formulation of Perfalgan® except for the conversion of 
the oxygen scavenger cysteine to cystine. The octanol:water partition coefficient likewise stayed constant and was in agreement 
with the value of 0.46–0.49 quoted in the literature.
Conclusion: Paracetamol and the excipients in Perfalgan® did not degrade on exposure to air and other stressors over 24 hours. 
The drug retained its lipid permeability over this period.
Keywords: excipients, high-performance liquid chromatography (HPLC), nuclear magnetic resonance (NMR), Perfalgan®, 
ultraviolet spectroscopy (UV spectroscopy)
Introduction
Oral paracetamol has analgesic and antipyretic properties and 
weak anti-inflammatory activity.1 It has been used in the 
perioperative period because of its presumed opioid-sparing 
effect.2 Until recently paracetamol was unavailable in the 
intravenous form due to its poor water solubility.3 Improved 
stabilisation techniques have recently allowed development of 
paracetamol as an intravenous form. In South Africa intravenous 
paracetamol is marketed by Bristol-Myers Squibb as Perfalgan®. 
According to the manufacturers,4–6 the main excipients are 
mannitol (which aids solubility), cysteine hydrochloride 
(preservative and antioxidant) and nitrogen as the resident gas 
in the vial to eliminate oxygen. Sodium phosphate, sodium 
hydroxide and hydrochloric acid are buffers used to maintain a 
pH of 5.5, minimising hydrolysis. Other intravenous paracetamol 
preparations exist. In North America intravenous acetaminophen 
(paracetamol) is marketed by Mallinckrodt Pharmaceuticals as 
Ofirmev®. The formulation has similarities to Perfalgan® in that it 
too contains 1  g of paracetamol and the main excipients are 
mannitol and cysteine.7
Bristol-Myers Squibb advise that Perfalgan® be infused over 15 
minutes and each vial be for single use only.8 No reason is given 
for this. Presumably there are concerns over the degradation of 
the product as well as sterility as the vial contains no antimicrobial 
agent.
Much work has been performed on the stability of oral 
paracetamol alone and in combination drugs, with liquid 
chromatography being the most widely accepted method.9,10 A 
PubMed search revealed limited research on intravenous 
paracetamol stability. Kwiatkowski, Johnson and Wagner tested 
samples of intravenous paracetamol with HPLC after exposure to 
air.11 Some 99% of the initial paracetamol concentration 
remained when tested over a period of 84 hours. Bernard et al. 
examined intravenous paracetamol in infusion sets during the 
infusion and after 24 hours of stasis within the set.12 
Chromatographic analysis revealed paracetamol to be stable. 
The authors propose that successive doses of paracetamol may 
be infused through an administration set as the drug is stable. 
No work was found focusing on the stability of intravenous 
paracetamol on exposure to heat or other stressors, or on the 
excipients in Perfalgan®.
Purpose of study
The purpose of this study was to measure the chemical and 
physical changes of Perfalgan® over time via three distinct 
components:
Part 1: Stability study of pure paracetamol and Perfalgan® over 
time.
Part 2: Stability study of excipients over time, which may impact 
on solubility or bioavailability.
Part 3: Bioavailability study of Perfalgan® as indicated by 
penetration of paracetamol into a lipid layer.
Method
1. Paracetamol stability testing
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Paracetamol stability was tested under ‘unstressed’ and ‘stressed’ 
conditions. The ‘unstressed’ sample was drawn from a vial that 
was exposed to air, simulating normal use. This was termed 
standard conditions. ‘Stressing’ refers to placing the drug under 
conditions that may force it to degrade or alter its structure, 
namely by adding acid, alkali, or an oxidising agent and exposing 
to dry heat. This was termed a forced degradation study. The 
purpose of forced degradation was to test, in the case of no 
degradation of paracetamol under ‘unstressed’ conditions, 
whether it was possible to detect change under extreme 
conditions. 
Stability testing therefore had four limbs as depicted in Figure 1.
The methodology used was derived from work performed by Shah 
et al.10 Reverse-phase high-performance liquid chromatography 
with an ultraviolet detector (RP-HPLC, Company: Agilent, Head 
quarters: Santa Clara, United States of America)-UV was used to 
quantify paracetamol. The SpectraSERIES 200 system used a mobile 
phase of 0.05 M potassium hydroxide phosphate:methanol (40:60 
v/v) and a Thermo Electron Corporation C18 column. Eluents were 
monitored at 266 nm. The retention time (tR) of paracetamol was 
expected to be approximately 2.7 minutes.
Limb one: paracetamol under standard conditions:
Calibration curves were created by analysing paracetamol stock 
solution of varying concentrations, by plotting peak area with 
concentration. An R2 value of better than 0.95 was regarded as 
acceptable. Integration of the area under the peak yielded the 
paracetamol concentration.
Limb two: Perfalgan® under standard conditions:
Perfalgan® stock solution was similarly analysed. The paracetamol 
peak was examined in a sample of stock solution at 0 hours and 
24 hours.
Limb three: paracetamol forced degradation study:
According to Shah et al. paracetamol does not degrade when 
exposed to acid, base, heat and oxidative stress.10 In our study, 
forced degradation analysis was carried out by subjecting 
paracetamol stock solution to acid (1 N HCl) and alkali (1 N NaOH) 
hydrolysis, chemical oxidation (3% H202) and dry heat (80°C for 30 
minutes). The HCl, NaOH and H2O2 were each mixed in a 2:1 ratio 
with paracetamol stock solution.
Limb four: Perfalgan® forced degradation study:
The forced degradation study was repeated with Perfalgan® at 
the same ratios and the samples studied to determine whether 
significant degradation had occurred.
2. Excipient stability testing
1H NMR (nuclear magnetic resonance) was used to analyse the 
changes in the concentration of cysteine and mannitol in 
Perfalgan® over time. A Bruker 400 1H NMR spectrometer locked 
on to the deuterium signal was used. The Perfalgan® ‘stressed’ 
and ‘unstressed’ solutions were mixed with deuterium oxide 
(D2O) for analysis.
3. Bioavailability testing
Paracetamol is believed to have predominantly central 
nervous system activity. Penetration into a lipid layer is 
therefore necessary for the effect to take place. Octanol is a 
hydrophobic organic solvent frequently used for 
pharmaceutical bioavailability testing. A drug’s penetration 
into the organic layer relative to the hydrophilic layer is 
measured via the octanol:water partition coefficient. 
According to the literature, the octanol:water partition 
coefficient (logPow) of paracetamol is 0.46–0.49.
13 In this study 
octanol was added to the paracetamol and Perfalgan® stock 
solution and UV spectroscopy performed on the aqueous and 
lipid (or organic) layers to assess the concentration of 




The paracetamol in Perfalgan® was clearly identified. Figures 2 
and 3 show the chromatograms developed. The similarities of 
the tR identified the paracetamol in the Perfalgan® within the 
limits of experimental error.
Using the calibration curve generated from analysis of pure 
paracetamol, the concentration of paracetamol in Perfalgan® 
was calculated. The calibration curve yielded a straight line with 
the equation of y = 47524x + 8 × 106. The R2 value was 0.98.
The chromatogram of Perfalgan® on exposure to air shows that 
no degradation of paracetamol occurred after 24 hours (cf. 
Figure 4).
Figure 1: Four limbs of stability testing.
Note: ‘Standard conditions’ is synonymous with ‘unstressed’ and ‘forced degradation 
study’ with ‘stressed’, as described in the text.
Figure 2: Chromatogram of paracetamol 513 μg.ml−1 at 0 hours.
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Table 1 shows high standard errors due to the standard deviation 
of the slope. The measured concentration of paracetamol was in 
keeping with that reported by the manufacturers. Within the 
experimental error there was no loss of paracetamol over 24 
hours.
Chromatograms were generated for paracetamol and Perfalgan® 
under stressed conditions as per limbs 3 and 4 of the study. The 
chromatograms of paracetamol remained unchanged after 
exposure to heat, acid, base and H2O2. This was in agreement 
with extensive literature on paracetamol stability and therefore 
will not be discussed further. The chromatograms of heated 
Perfalgan® showed no degradation. On exposure to acid there 
was visible precipitation within the Perfalgan® sample. The HPLC 
results confirmed this with < 10% of the paracetamol remaining 
in solution. Although the HPLC results showed a decrease in the 
concentration they also showed the same tR and that no 
degradation peaks were present. The same chromatogram was 
obtained after 24 hours. Due to the precipitation, the calibration 
curve was not applied as concentrations calculated would be 
meaningless. Mixing the standard solution of Perfalgan® with 
base resulted in copious precipitation. While the supernatant 
could have been analysed by HPLC, judging by the amount of 
precipitate it was concluded that all the paracetamol had 
precipitated. Given this assumption and the danger of using 
high concentrations of base on the HPLC column it was decided 
not to proceed further with this experiment. Hydrogen peroxide 
caused splitting of the paracetamol peak (Table 2).
Summary of HPLC findings
Quantitative analysis of the paracetamol in Perfalgan® proved 
difficult using HPLC due to precipitation in the acid-stressed and 
base-stressed samples and splitting of the peak as in the case of 
H2O2 exposure. However, quantitative results from the unstressed 
and heat-stressed samples confirmed the concentration of 
paracetamol in vial to conform to the manufacturer’s 
specification. No loss was seen with time. Qualitative analysis 
showed that samples had the same tR and no degradation 
products of paracetamol were seen.
1H NMR results
1H NMR spectra were created from analysis of ‘stressed’ and 
‘unstressed’ samples of Perfalgan®. The X-axis shows the proton 
chemical shift, which is a measure of the magnetic shielding of 
the nucleus and hence its chemical environment. The Y-axis 
shows the absorption intensity. The area under the peak is 
proportional to the number of protons in the compound. 
Standard tables14 were used to identify the main constituents in 
Figure 3: Chromatogram of Perfalgan® 476 μg.ml−1 at 0 hours.
Figure 4: Chromatogram of Perfalgan® 476 μg.ml−1 at 24 hours.
Table 1: Comparison between the area under the peak measured by HPLC (in million units) and the paracetamol concentration (in μg.ml−1) in 
Perfalgan® at 0 and 24 hours
Factor Standard
0 hours 24 hours
Area under peak 32.4 36.4
Concentration 520 600
Standard error 50 50
95% confidence interval 220 230
Table 2: Comparison between the area under the peak measured by HPLC (in million units) and the paracetamol concentration (in μg.ml−1) in 
Perfalgan® on exposure to dry heat
Factor Heat stressed
0 hours 24 hours
Area under peak 33.14 33.05
Concentration 502.7 501.1
Standard error 50 50
95% confidence interval 230 230
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cysteine was converted to cystine within 1 hour with addition of 
hydrogen peroxide, 12 hours with heating and 48 hours in the 
unstressed sample. There was no change in the paracetamol or 
mannitol in any samples.
UV spectroscopy results
The HPLC instrument used in our study could only look at a 
single wavelength, which was chosen to be that of paracetamol. 
It is therefore possible that degradation products absorbing at 
different wavelengths could have been missed. For this reason 
ultraviolet spectroscopy was used to assess the samples in the 
wavelength range 200 to 800 nm. At the same time, since UV can 
be quantitative, the experiments were also used to check the 
HPLC quantitation.
Perfalgan®, namely paracetamol, cysteine and mannitol. In 
Figures 5 and 6 the cysteine spectrum is shown as an insert at 
two hundred times magnification as its concentration is much 
lower than the other two constituents. Where two time periods 
are shown on the same figure, the spectra are offset slightly for 
clarity. Using integration of the 1H NMR data, it was possible to 
calculate the concentration of each constituent in Perfalgan® as 
the concentration of paracetamol is known to be 10 mg.ml−1 (cf. 
Table 3).
The spectra of Perfalgan® did not change significantly over time 
or on stressing. The only change was that on exposure to air, over 
time, cysteine oxidised to form cystine. This change occurred 
more quickly on exposure to heat and hydrogen peroxide. All 
Figure 5: 1H NMR spectrum of Perfalgan®.
Figure 6: 1H NMR spectrum of Perfalgan® at 0 hours and after 48 hours of exposure to air.
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Summary
The concentration of paracetamol penetrating the lipid or 
aqueous layer remained constant despite stress applied to the 
Perfalgan® samples over 24 hours. This implies that bioavailability 
was unaltered.
Discussion
Each method of analysis showed a well-defined peak for 
paracetamol. The tR using HPLC was in the range of 3.2 to 3.3 
minutes, which correlated well with that found in the literature. 
Although subjected to extreme conditions the paracetamol in 
Perfalgan® did not degrade.
A variety of methods was used to analyse Perfalgan® in this 
study. While HPLC was more accurate than UV spectroscopy 
(with an R2 value of the calibration curve of 0.98 as opposed to 
0.94 and smaller standard error) it was limited by the fact that it 
analysed paracetamol at only one wavelength, 266 nm.
HPLC results
The paracetamol in Perfalgan® did not degrade significantly over 
a 24-hour period on exposure to air. Of the stressed samples, the 
paracetamol in heated Perfalgan® was unchanged. The 
Perfalgan® was found to precipitate in base precluding further 
analysis with HPLC. Filtered samples showed very small peaks at 
the same retention time due to loss of paracetamol by the 
filtering process. The precipitation may be the paracetamol alone 
or contain buffer from the mobile phase. Further studies with 
different mobile phases would need to be done to elucidate this.
As with HPLC the equipment was calibrated with altering 
concentrations of paracetamol at 245  nm. The equation of the 
straight line was y = 0.0424x  +  0.0141. The R2 value was 0.94, 
making it a less precise method than HPLC. The standard error 
was also greater than the HPLC at 0.02. For this reason HPLC was 
used as the main method for quantifying paracetamol.
UV spectroscopy was first performed on paracetamol mixed in 
octanol to create a calibration curve, which yielded a straight line 
with equation of y = 0.2812x – 0.6718. The R2 value is 0.97 making 
it an accurate calibration curve. UV spectroscopy was then 
performed on ‘stressed’ and ‘unstressed’ Perfalgan® samples 
mixed with octanol. Since Perfalgan® is formulated in water, the 
octanol formed a layer above the aqueous layer. Each layer was 
analysed for paracetamol (cf. Figure 7). (In the key ‘pf’ represents 
Perfalgan®.)
Using the paracetamol:octanol calibration curve it was possible 
to calculate the concentration of paracetamol recovered in each 
Perfalgan® sample. The concentration in the organic (or octanol) 
layer was subtracted from the known total concentration of 
4.76 μg.ml−1 in the stock solution to give the concentration in the 
aqueous layer. Although measurements of each layer (i.e. organic 
and aqueous layer) could have been performed it is common 
practice to measure the concentration of a drug in one layer and 
calculate the concentration in the other. The ratio of these two 
values is the octanol:water partition coefficient. The coefficient is 
often also given as the log of this value. The samples show good 
agreement with the literature where the partition coefficient 
(logPow) of paracetamol is quoted as 0.46–0.49 (Table 4).
15,16
Table 3: Comparison of the major three constituents in Perfalgan® 
Note: The concentrations of mannitol and cysteine in Ofirmev® are roughly twice that of Perfalgan®.
Constituent Molar ratio derived by 1H NMR Molecular weight (g.mol−1) Concentration (mg.ml−1) Concentration (mM)
Paracetamol 1 151.17 10 66.15
Mannitol 1.24 182.17 14.97 82.18
Cysteine 0.004 121.16 0.03 0.25
Figure 7: UV spectrum of the organic layer in 50:50 Perfalgan®:octanol.
Table 4: Comparison of log Pow of various Perfalgan® samples
Notes: Calculations were performed on numbers to three decimal places. This table shows only the first two decimal places.
pf:oct 0hr pf:oct 24hr pf:oct acid 0hr pf:oct acid 24hr pf:oct H2O2 pf:oct heat
logPow 0.48 0.46 0.36 0.43 0.57 0.56
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agreement with the literature, which quotes the figure between 
0.46 and 0.49. The logPow values for H2O2-treated and heat-
treated Perfalgan® were about 20% greater than unstressed. 
LogPow values of  <  1 indicate high solubility, 1–3 moderate 
solubility and 3–5 low solubility. Within this context it is clear that 
this increase does not have a significant impact on the drug’s 
solubility.
Conclusions
In summary, three different assay methods showed the 
paracetamol in Perfalgan® was stable with regard to its structure, 
concentration and bioavailability over a 24-hour period and 
despite changing its environment. It follows that the practice of 
using a single vial of Perfalgan® multiple times over the course of 
a day will render a constant concentration of paracetamol, of 
equal bioavailability at the end of the day relative to a newly 
opened vial. The practice of using Perfalgan® as a multidose vial 
is therefore valid from a chemical point of view. Concerns about 
under-dosing children from a previously opened vial are invalid.
Sterility may be a legitimate barrier to the clinical application of 
this process and further microbiological testing should be 
performed before this practice can be fully endorsed.
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